MCUR1 is a prognostic biomarker for ovarian cancer patients

2021 ◽  
pp. 1-6
Author(s):  
Liming Fan ◽  
Hualiang Yang ◽  
Bo Zhang ◽  
Hong Ding
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Immune Cell ◽  
Prognostic Biomarker ◽  
Cancer Prognosis ◽  
High Expression Group ◽  
Potential Biomarker ◽  
Patient Specimen ◽  
Ovarian Cancer Prognosis ◽  
Low Expression

PURPOSE: To propose MCUR1 gene as a potential biomarker for ovarian cancer prognosis. METHODS: The ovarian cancer patient specimen from TCGA database were analyzed using survival analysis. The immune cell infiltration ratio and checkpoints had also been investigated for different expression group of MCUR1. The function of MCUR1 as a ovarian cancer prognosis biomarker was verified in clinic. RESULTS: The low expression of MCUR1 was associated with the poor prognosis of ovarian cancer patients. The expressions of majority of immune cells and 6 checkpoints in low expression group of MCUR1 were significantly lower than that in high expression group of MCUR1 (P< 0.05). The MCUR1 could be utilized as a prognostic biomarker for ovarian cancer patients in clinic. CONCLUSION: This study has proposed a potential prognostic biomarker for ovarian cancer patients, which offers a beneficial reference for future ovarian cancer administration.

scholarly journals Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis

Oncotarget ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 18773-18791 ◽  
Author(s):  
Michael Kleemann ◽  
Jeremias Bereuther ◽  
Simon Fischer ◽  
Kim Marquart ◽  
Simon Hänle ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Prognosis ◽  
Tissue Specific ◽  
Specific Effects ◽  
Potential Biomarker ◽  
Micro Rnas ◽  
Ovarian Cancer Prognosis

scholarly journals M6A “Writer” Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Changjing Cai ◽  
Jie Long ◽  
Qiaoqiao Huang ◽  
Ying Han ◽  
Yinghui Peng ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Immune Cell ◽  
Prognostic Biomarker ◽  
Rna Modification ◽  
Immune Infiltration ◽  
The Impact ◽  
Tumor Related Death ◽  
Low Expression

Rectal cancer (RC) is the leading cause of tumor-related death among both men and women. The efficacy of immunotherapy for rectal cancer is closely related to the immune infiltration level. The N6-methyladenosine (m6A) modification may play a pivotal role in tumor-immune interactions. However, the roles of m6A-related genes in tumor-immune interactions of rectal cancer remain largely unknown. After an evaluation on the expression levels of m6A-related genes and their correlations with the prognosis of rectal cancer patients, we found that METTL14 was the only gene to be significantly correlated with prognosis in rectal cancer patients. Therefore, we further observed the impact of METTL14 expression and m6A modification on the immune infiltration in rectal cancer. Our study indicates that low expression of the m6A “writer” gene METTL14 in rectal cancer may lead to the downregulation of m6A RNA modification, thus reducing the level of immune cell infiltration and resulting in poor prognosis. METTL14 expression level is an independent prognostic factor in rectal cancer and is positively correlated with the immune infiltration level. Our study identified METTL14 as a potential target for enhancing immunotherapy efficacy in rectal cancer.

scholarly journals Plasma MicroRNA-200c as A Prognostic Biomarker for Epithelial Ovarian Cancer

2019 ◽  
Vol 11 (3) ◽  
pp. 267-72
Author(s):  
Addin Trirahmanto ◽  
Hariyono Winarto ◽  
Aria Kekalih ◽  
Ferry Sandra
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Prognostic Biomarker ◽  
Quantitative Polymerase Chain Reaction ◽  
Cancer Prognosis ◽  
Ca 125 ◽  
Lower Survival Rate ◽  
Main Regulator ◽  
New Biomarkers ◽  
Ovarian Cancer Prognosis

BACKGROUND: Ovarian cancer is the 8th most prevalent cancer in women in the world. Current biomarker prognosis for ovarian cancer has numerous limitations, thus new biomarkers are needed. MicroRNAs (miRs) are considered as potential biomarkers in ovarian cancer as they are stable in blood. One candidate is miR-200c, the main regulator in epithelial transition to the mesenchyme. The aim of this study is to determine the role of miR-200c as prognostic biomarker for epithelial ovarian cancer (EOC).METHODS: This is a prospective cohort study conducted at Dr. Sardjito Central General Hospital in Yogyakarta from September 2015 to July 2018. Sampling was done using consecutive sampling method. Forty plasma samples of EOC subjects were included in this study. miR-200c expression was quantified using Reverse Transcriptase Quantitative Quantitative Polymerase Chain Reaction (RTqPCR) with miR-16 as the reference gene.RESULTS: The expression of miR-200c was significantly higher in the group of subjects with preoperative CA-125 levels >500 U/mL (p=0.009) than the group of subjects with preoperative CA-125 levels <500 U/mL. Subjects with higher miR-200c expression had lower survival rate than subjects with lower miR-200c expression, although not statistically significant.CONCLUSION: The miR-200c could be a promising biomarker for EOC. Further studies with larger sample sizes are needed to clarify the prognostic value of miR200c.KEYWORDS: miR-200c, epithelial ovarian cancer, prognosis, overall survival

scholarly journals Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples

2020 ◽  
Author(s):  
Qiang Liu ◽  
Yihang Qi ◽  
Jie Zhai ◽  
Xiangyi Kong ◽  
Xiangyu Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Cancer Immunotherapy ◽  
Cancer Patients ◽  
Immune Cell ◽  
Immune Checkpoints ◽  
Cell Populations ◽  
Potential Biomarker ◽  
The Impact

Abstract Background Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a large number of cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, is a protein Coding gene served as alternative inhibitory receptors to be targeted in the clinic. The impact of LAG3 on immune cell populations and co-regulation of immune response in breast cancer remained largely unknown. Methods To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from a total of 2994 breast cancer patients. Results We observed that LAG3 was closely correlated with major molecular and clinical characteristics, and was more likely to be enriched in higher malignant subtype, suggesting LAG3 was a potential biomarker of triple-negative breast cancer. Furthermore, we estimated the landscape of relationship between LAG3 and ten types of cell populations in breast cancer. Gene ontology analysis revealed LAG3 were strongly correlated with immune response and inflammatory activities. We investigated the correlation pattern between LAG3 and immune modulators in pan-cancer, especially the synergistic role of LAG3 with other immune checkpoints members in breast cancer. Conclusions LAG3 expression was closely related to malignancy of breast cancer and might serve as a potential biomarker; LAG3 might plays an important role in regulating tumor immune microenvironment, not only T cells, but also other immune cells. More importantly, LAG3 might synergize with CTLA4, PD1/ PDL1 and other immune checkpoints, thereby lending more evidences to combination cancer immunotherapy by targeting LAG3, PD1/PDL1, and CTLA4 together.

scholarly journals Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study

Aging ◽  
2015 ◽  
Vol 7 (12) ◽  
pp. 1066-1074 ◽  
Author(s):  
Claire Falandry ◽  
Béatrice Horard ◽  
Amandine Bruyas ◽  
Eric Legouffe ◽  
Jacques Cretin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Telomere Length ◽  
Cancer Patients ◽  
Prognostic Biomarker ◽  
Advanced Ovarian Cancer

scholarly journals Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma

2016 ◽  
Vol 40 (3-4) ◽  
pp. 707-715 ◽  
Author(s):  
Ruyi Huang ◽  
Xiaochen Wang ◽  
Wenjie Zhang ◽  
Guangyan Zhangyuan ◽  
Kangpeng Jin ◽  
...  
Keyword(s):  
Roc Curve ◽  
Cox Regression ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Diagnosis And Prognosis ◽  
Kaplan Meier ◽  
High Expression Group ◽  
Negative Prognostic Factor ◽  
Potential Biomarker ◽  
Low Expression

Background/Aims: Long non-coding RNAs (lncRNAs) have been reported to play pivotal roles in multiple tumors and can act as tumor biomarkers. In this study, we explored the association of the expression of an lncRNA, DGCR5 with clinicopathological features and prognosis in HCC. Methods: Expression levels of DGCR5 were detected by quantitative real-time PCR (qRT-PCR) and the clinical data was obtained, including basic information, data of clinicopathology and cancer specific survival rate. Receiver operating characteristic (ROC) curve, Kaplan-Meier methods and multivariable Cox regression models were used to analyze predictive efficiency, long-term survival outcomes and risk factors. Results: DGCR5 was found down-regulated in HCC tissues (P<0.001) and serum (P = 0.0035) and low expression of DGCR5 was correlated with a poor cancer specific survival (CSS) (P = 0.0019), as the overall 5-year CSS rates were 10.3% (low expression group) and 36.6% (high expression group), respectively. A stratified analysis demonstrated that low DGCR5 expression was an independent negative prognostic factor for HCC. In addition, the area under the ROC curve was 0.782 with a sensitivity of 0.633 and a specificity of 0.833. Conclusions: Our results suggest that DGCR5 may be a participator in HCC and can serve as potential biomarker for the diagnosis and prognosis in HCC.

Common analgesics and ovarian cancer prognosis – Authors' reply

2018 ◽  
Vol 19 (10) ◽  
pp. e507
Author(s):  
Melissa A Merritt ◽  
Shelley S Tworoger
Keyword(s):  
Ovarian Cancer ◽  
Cancer Prognosis ◽  
Ovarian Cancer Prognosis

Worsening of ovarian cancer prognosis with age: an exploration of pharmacokinetics, body composition, and biology

2021 ◽  
Vol 12 (8) ◽  
pp. S6
Author(s):  
M. Extermann ◽  
C. Walko ◽  
A. Mishra ◽  
K. Thomas ◽  
B. Cao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Body Composition ◽  
Cancer Prognosis ◽  
Ovarian Cancer Prognosis
Sign in / Sign up

Export Citation Format

Share Document